Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 2, 2015, Pages 126-131

  Hitchings, Andrew W ^a   Archer, John R H ^a,b   Srivastava, Shelley A ^a,c   Baker, Emma H ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Adverse drug reaction; Lactic acid; Metformin; Obstructive pulmonary diseases; Survival; Type 2 Diabetes Mellitus

Indexed keywords

LACTIC ACID; METFORMIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CORTICOSTEROID; INSULIN; MEGLITINIDE; SULFONYLUREA;

AGED; APACHE; ARTERIAL GAS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HOSPITAL; HUMAN; HYPOXEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RESPIRATORY ACIDOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL; ACIDOSIS, LACTIC; ADULT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; ALL CAUSE MORTALITY; CONCENTRATION (PARAMETER); CONTROLLED STUDY; DISEASE EXACERBATION; FOLLOW UP; HOSPITAL ADMISSION; MEDIAN SURVIVAL TIME;

ACIDOSIS, LACTIC; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; MALE; METFORMIN; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84928950422     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2015.898052     Document Type: Article

References (25)

1. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. In: Rabe KF, Wedzicha JA, Wouters EF, editors. European Respiratory Monograph COPD and Comorbidity. 59. Sheffi eld, UK: European Respiratory Society Journals Ltd., 2013.
2. Manni no DM, Th orn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32(4):962-969.
3. Kinne y GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, et al. Pulmonary Function Reduction in Diabetes Mellitus with and without Chronic Obstructive Pulmonary Disease. Diabetes Care 2014;37:389-395.
4. Ameri can Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes Care 2013;36(Supplement 1):S11-S66.
5. Natio nal Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians of London, 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53885/.
6. Holma n RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-1589.
7. Baile y CJ, Grant PJ, Evans M, De Fine Olivarius N, Andreasen A, Fowler P, et al. Th e UK prospective diabetes study. Lancet 1998;352(9144):1932-1934.
8. Sexto n P, Metcalf P, Kolbe J. Respiratory eff ects of insulin sensitisation with metformin: A prospective observational study. COPD: Journal of Chronic Obstructive Pulmonary Disease 2014;11:133-142.
9. Kim H J, Lee JY, Jung HS, Kim DK, Lee SM, Yim JJ, et al. Th e impact of insulin sensitisers on lung function in patients with chronic obstructive pulmonary disease and diabetes. Int J Tuberc Lung Dis 2010;14(3):362-367.
10. Huan g NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009;134(2):169-175.
11. Isod a K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinfl ammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Th romb Vasc Biol 2006;26(3):611-617.
12. Myer burg MM, King JD, Jr., Oyster NM, Fitch AC, Magill A, Baty CJ, et al. AMPK agonists ameliorate sodium and fl uid transport and infl ammation in cystic fi brosis airway epithelial cells. Am J Respir Cell Mol Biol 2010;42(6):676-684.
13. Form oso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008;24(3):231-237.
14. Bonn efont-Rousselot D, Raji B, Walrand S, Gardes-Albert M, Jore D, Legrand A, et al. An intracellular modulation of free radical production could contribute to the benefi cial eff ects of metformin towards oxidative stress. Metabolism 2003;52(5):586-589.
15. Garn ett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, et al. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of eff ects on blood glucose. Th orax. 2013;68(9): 835-845.
16. Brit ish National Formulary (online). London: BMJ Group and Pharmaceutical Press;2013. Available from: http://www.bnf. org/bnf/index.htm.
17. Bris tol-Myers Squibb Company. Glucophage (metformin hydrochloride) tablets package insert, Princeton, NJ, USA, 2009. Available from: http://packageinserts.bms.com/pi/pi- glucophage.pdf.
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2diabetes mellitus. Cochrane Database Syst Rev. 2010(4). doi: 10.1002/14651858.CD002967.pub4.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-383.
20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classifi cation system. Crit Care Med 1985;13(10):818-829.
21. Mongraw-Chaffi n ML, Matsushita K, Brancati FL, Astor BC, Coresh J, Crawford SO, et al. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS ONE 2012;7(12):e51237.
22. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. Th e relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: Th e Fremantle Diabetes Study. Br J Clin Pharmacol 2001;52(2):137-144.
23. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobicallypoised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008;233(2):203-210.
24. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002;13(7):428.
25. Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T, Lindberg E, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 2007;101(9):1954-1960.